Loading
Sentiment · FY2026 Q3
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Charles Rhyee | TD Cowen | 8 (13%) |
| Elizabeth Anderson | Evercore ISI | 8 (0%) |
| Erin Wright | Morgan Stanley | 8 (0%) |
| George Hill | Deutsche Bank | 8 (0%) |
| Eric Percher | Nephron Research | 8 (0%) |
| Kevin Caliendo | UBS | 8 (38%) |
| Mike Cherny | Leerink Partners | 8 (0%) |
| Lisa Gill | JPMorgan | 8 (0%) |
| Daniel Grosslight | Citigroup | 7 (0%) |
| Allen Lutz | Bank of America | 7 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Nephron Research | 1 | 8 (0%) |
| UBS | 1 | 8 (38%) |
| Morgan Stanley | 1 | 8 (0%) |
| TD Cowen | 1 |
| 8 (13%) |
| Deutsche Bank | 1 | 8 (0%) |
| Evercore ISI | 1 | 8 (0%) |
| JPMorgan | 1 | 8 (0%) |
| Leerink Partners | 1 | 8 (0%) |
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $79.05B | +14.7% | $0.02 | -99.0% | 2.7% | 0.9% | 0.0% | $818M |
| FY2025 Q1 | $81.49B | +12.8% | $2.50 | -16.1% | 2.8% | 1.0% | 0.6% | $-2.82B |
| FY2025 Q2 | $75.45B | +10.3% | $3.68 | +76.1% | 3.5% | 1.3% | 1.0% | $3.22B |
| FY2025 Q3 | $80.66B | +8.7% | $3.52 | +45.5% | 3.3% | 1.2% | 0.9% | $-74M |
| FY2025 Q4 | $83.73B | +5.9% | $-1.75 | -10333.9% | 3.1% | 1.0% | -0.4% | $2.88B |
| FY2026 Q1 | $85.93B | +5.5% | $2.87 | +14.8% | 3.3% | 1.2% | 0.7% | $-2.42B |
| FY2026 Q2 | $78.36B | +3.8% | $8.40 | +128.3% | 4.2% | 1.7% | 2.1% | $1.17B |
| FY2026 Q3 | $84.75B | +5.1% | $3.94 | +11.9% | 4.3% | 1.3% | 0.9% | $2.43B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Cencora posted Q2 revenue of $78.4 billion, up 4%, with adjusted diluted EPS of $4.75 reflecting 7.5% growth. Revenue growth slowed on multiple fronts, but core U.S. operating income growth remained within the long-range plan. The company raised full-year EPS guidance to $17.65 to $17.90, progressed on the MWI divestiture and portfolio optimization, and saw the international segment return to strong growth. GLP-1 sales increased $1.9 billion year-over-year.
Competitive Dynamics | M&A | Revenue Growth | Guidance Reliability | Demand | Margin | Pricing | Regulation Policy | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 6 | 3 | 3 | 1 | 3 | 1 | 3 | |
| 2025Q1 | 9 | 3 | 4 | 5 | 3 | |||
| 2025Q2 | 6 | 3 | 4 | 1 | 4 | 2 | 1 | 1 |
| 2025Q3 | 4 | 3 | 6 | 2 | 1 | 2 | 3 | 3 |
| 2025Q4 | 4 | 6 | 1 | 4 | 1 | 3 | 1 | |
| 2026Q1 | 3 | 7 | 3 | 5 | 1 | 1 | 2 | 2 |
| 2026Q2 | 5 | 2 | 1 | 3 | 3 | 4 | 3 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | |
|---|---|---|---|---|---|---|---|
| Competitive Dynamics | 6 | 9 | 6 | 4 | 4 | 3 | 5 |
| M&A | 3 | 3 | 3 | 3 | 6 | 7 | 2 |
| Revenue Growth | 3 | 4 | 4 | 6 | 1 | 3 | 1 |
| Guidance Reliability | 1 | 5 | 1 | 2 | 4 | 5 | 3 |
| Demand | 3 | 3 | 4 | 1 | 1 | 1 | 3 |
| Margin | 2 | 2 | 3 | 1 | 4 | ||
| Pricing | 1 | 1 | 3 | 1 | 2 | 3 | |
| Regulation Policy | 3 | 1 | 3 | 2 |
What COR and other companies said about each other on FY2026 Q2 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“we're very pleased to have announced the South acquisition, and we see very good bolt-on opportunities for our MSO businesses over time”
Cencora announced the South (iSouth) MSO acquisition (not yet in FY26 guidance) and sees further bolt-on opportunities across its MSO platform.
“the February 2026 acquisition of OneOncology”
Cencora's February 2026 acquisition of OneOncology lifted consolidated gross margin and is expected to ramp accretion over the fiscal year as it integrates with the RCA MSO platform.
“the agreement to merge MWI Animal Health with Covetrus”
Cencora agreed to merge its MWI Animal Health business with Covetrus, part of its portfolio optimization toward a pharmaceutical-centric strategy.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
COR Cencora | 8 | +3.9% | |
| CAH Cardinal Health | 9 | +11.1% | |
| HSIC Henry Schein | 6 | +6.3% | |
| MCK McKesson Corporation | 8 | +6.0% |